Sunday - May 4, 2025

LOGIN  |  REGISTER
C4 Therapeutics

CVS Health to present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023 | Last Trade: US$67.46 1.99 -2.87

WOONSOCKET, R.I., Dec. 19, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that President and CEO Karen S. Lynch and Interim Chief Financial Officer Thomas F. Cowhey will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at approximately 7:30 a.m. Pacific Time.

An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.

About CVS Health

CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individuals with their health – whether that's managing health conditions, staying compliant with their medications or accessing affordable health services in the most convenient ways. Our goal is to create seamless connections across the health care system, simplifying the experience and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page